Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 3/20 | 0.57 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.57 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 4/20 | 0.56 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | TNNI3 | P19429 | 2/20 | 0.56 |
| ▸ | TNNT2 | P45379 | 2/20 | 0.56 |
| ▸ | TNNC1 | P63316 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281885 | 0.87 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL29382560 | 0.87 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL28176940 | 0.87 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL8659653 | 0.87 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL8654543 | 0.87 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL244406 | 0.87 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL14164007 | 0.87 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL8654092 | 0.87 | SLC5A2 (0.64) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL941002 | 0.84 | SLC28A3 (0.62) | SLC5A2SLC5A1SLC28A3USP2HKDC1 | |
| SCHEMBL7039100 | 0.83 | SLC5A2 (0.56) | SLC5A2SLC5A1SLC28A3HIF1ATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461207-B2 | Phloroglucinol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-8278356-B2 | — | — | 2012-10-02 | — | — | US | disclosed |
| EP-1732882-B1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-1940372-B1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110142765-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-16 | — | — | US | disclosed |
| US-7923473-B2 | Moderate binding of selectins ; chronic obstructive pulmonary disease; Crohn's disease; sepsis; antiinflammatory agents; skin disorders; antiarthritic agents; cardiovascular disorders; autoimmune diseases ' | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-04-12 | — | — | US | disclosed |
| WO-2007039114-A1 | NOVEL NITROCATECHOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039113-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039112-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1764095-A1 | Novel nitrocatechol derivatives having selectin ligand activity | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764096-A1 | Novel phloroglucinol derivatives having selectin ligand activity | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764094-A1 | Novel multi-cyclic compounds and their use | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764093-A1 | Novel aromatic compounds and their use in medical applications | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1732882-A1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Revotar Biopharmaceuticals AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090284-A1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2005-09-29 | — | — | WO | disclosed |
| EP-1577289-A1 | Non-glycosylated/-glycosidic/-peptidic small molecule selectin inhibitors for the treament of inflammatory disorders | Revotar Biopharmaceuticals AG (DE) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | SELP, SELL, SELE | SLC5A2 630/4885SLC5A1 518/4885SLC28A3 447/4885 |
| US-20110142765-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | SELPLG, SELP, SELL | SLC5A2 87/4885SLC5A1 62/4885SLC28A3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.